| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22015 |
| Drug | Tixagevimab /cilgavimab |
| Brand | Evusheld® |
| Indication | For the pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg. |
| Assessment Process | |
| Rapid review commissioned | 09/03/2022 |
| Rapid review completed | 11/04/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tixagevimab/cilgavimab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/04/2022 |
| Pre-submission consultation with Applicant | 29/06/2022 |
| Full submission received from Applicant | 16/08/2022 |
| Preliminary review sent to Applicant | 28/10/2022 |
| NCPE assessment re-commenced | 28/11/2022 |
| Factual accuracy sent to Applicant | 12/12/2022 |
| NCPE assessment re-commenced | 19/12/2022 |
| NCPE assessment completed | 21/12/2022 |
| NCPE assessment outcome | The NCPE recommends that tixagevimab/cilgavimab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
